Atogepant for Pediatric Migraine

"This clinical trial's enrollment requirements stipulate that participants are aged between 6 and 17 years old. There are 31 studies available for minors, whereas those over 65 can choose from 106 different options."

"There is prior clinical evidence that attests to Atogepant Dose A (12-17 yrs)'s safety, thus it was evaluated as a 3 on our scale."

"Clinicaltrials.gov indicates that this investigation is not currently seeking patients, despite having been posted on March 9th 2023 and last updated on January 24th of the same year. However, 155 other research initiatives are actively enrolling participants at present."

"The recruitment phase of this trial is currently operating in 43 distinct medical centres. Areas close to Huntsville, Little Rock and Anaheim are among those enrolled; other sites exist throughout the United States. To reduce travel burden, it's best to choose a clinic located near you if you're interested in taking part."

"This clinical trial is aiming to recruit 250 minors aged between 6 and 17 who are suffering from migraine with aura. To be enrolled, participants must meet the following requirements: being between 6-17 years old (inclusive), having a history of episodic migraine, completing Study M21-201 or its PK substudy, weighing at least 20 kg but less than 135kg, presenting a past consistent with ICHD-3 diagnosis for more than half a year and deemed an appropriate candidate by their investigator to receive daily preventive treatment using Atogepant (except in de novo cases)."